Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

10.55B

Market cap10.55B

Price-Earnings ratio

-10.50

Price-Earnings ratio-10.50

Dividend yield

—

Dividend yield—

Average volume

2.08M

Average volume2.08M

High today

$75.92

High today$75.92

Low today

$73.46

Low today$73.46

Open price

$73.90

Open price$73.90

Volume

1.48M

Volume1.48M

52 Week high

$88.31

52 Week high$88.31

52 Week low

$35.22

52 Week low$35.22

Stock Snapshot

With a market cap of 10.55B, Cytokinetics(CYTK) trades at $75.87. The stock has a price-to-earnings ratio of -10.50.

During the trading session on 2026-08-18, Cytokinetics(CYTK) shares reached a daily high of $75.92 and a low of $73.46. At a current price of $75.87, the stock is +3.3% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 1.48M, compared to an average daily volume of 2.08M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $35.22.

CYTK News

Simply Wall St 3d

Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' Narrative

Cytokinetics, Incorporated previously reported second-quarter 2026 results showing revenue of US$28.62 million versus US$66.77 million a year earlier, alongside...

Nasdaq 4d

Cytokinetics Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

TipRanks 5d

Cytokinetics Files Patent Suit to Protect MYQORZO Franchise

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Analyst ratings

91%

of 23 ratings

Buy

91.3%

Hold

8.7%

Sell

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.